Tech Company Financing Transactions
Alys Pharmaceuticals Funding Round
Medicxi Ventures participated in a $100 million funding round for Alys Pharmaceuticals. The round was announced by the company on 2/12/2024.
Transaction Overview
Company Name
Announced On
2/12/2024
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
100 Northern Avenue
Boston, MA 02210
USA
Boston, MA 02210
USA
Phone
Undisclosed
Website
Email Address
Overview
Alys Pharmaceuticals is a pioneering force in immuno-dermatology, poised to redefine the treatment landscape with cutting-edge science and a robust R&D-centric multi-platform pipeline. Launched in February 2024, Alys emerges as a result of the strategic aggregation of 6 asset-centric companies backed by Medicxi.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Financial Officer
Nicola De Francesco
Chief Medical Officer
Lars French
Chief Operating Officer
Thibaud Portal
Chief Technical Officer
John Harris
Browse more venture capital transactions:
Prev: 2/12/2024: LeoLabs venture capital transaction
Next: 2/12/2024: Nucleus Security venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs